50 results about "Endometrial Carcinomas" patented technology

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This document relates to methods and materials for assessing and / or treating mammals (e.g., humans) having endometrial cancer. For example, methods and materials for identifying endometrial cancers likely to respond to a particular cancer treatment (e.g., a platinum based cancer therapy) are provided. This document also relates to materials and methods for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment.

The invention provides a construction method and application of an endometrial cancer CT image segmentation model. The construction method comprises the following steps: acquiring a plurality of endometrial CT images marked with canceration regions as a training data set; constructing an endometrial cancer CT image segmentation framework, wherein the endometrial cancer CT image segmentation framework is of a U-Net structure comprising a coding unit, a bottleneck layer and a decoding unit; and training the endometrial cancer CT image segmentation architecture by using the training data set to obtain an endometrial cancer CT image segmentation model. According to the scheme, multi-scale structure change information is explicitly captured by constructing a multi-direction coding structure response operator and generating a coding structure gradient field, and representation of thin and weak boundaries and small lesions is enhanced to improve the segmentation accuracy of the model.

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

The present disclosure provides methods, compositions, uses, and kits for treatment of solid cancer (e.g., urothelial cancer (UC), head and neck squamous cell carcinoma (HNSCC), cervical cancer (CC), endometrial carcinoma (EC), or triple-negative breast cancer (TNBC)) using anti-human Nectin-4 therapeutics.

The present application relates to the field of biotechnology, and more particularly to an inhibitory peptide targeting p53 protein and application thereof. The present application uses IDProMat to design and obtain the inhibitory peptide targeting p53 protein according to the core binding site of the binding interface of the p53 protein core domain and ASPP2, TSPYL5, iASPP and the like; the inhibitory peptide can bind to p53 protein, competitively block the interaction between E3 ubiquitin ligase COP1 and p53, inhibit the ubiquitination degradation of p53, restore the anticancer function of p53, and has good biological safety and metabolic stability, and is expected to be used for clinical treatment of ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer and the like.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The invention discloses a large model analysis system and method for endometrial cancer data management, and relates to the technical field of data large model analysis, and the method comprises the steps: determining the total amount of sample data; each group of sample data comprises characteristic data information of the patient and a judgment result of molecular typing data determined by adopting an immunohistochemical method; the features are divided based on the feature data information of the patient, the coincidence rate under each feature division is calculated, and a plurality of coincidence subintervals are formed based on the coincidence rates; and constructing a training model, forming the probability that the coincidence rate is in different coincidence subintervals based on different feature data information, forming a recommendation decision, and feeding back the recommendation decision to an administrator port. The method can solve the problem of significant subjectivity existing in a traditional mode of selecting a detection method only depending on the personal experience of doctors, establishes an objective decision standard through data driving, and reduces the selection deviation caused by the experience difference of the doctors.

The invention discloses an endometrial cancer typing system based on a multi-dimensional molecular marker, and the system comprises a data input module which is used for receiving multi-dimensional molecular marker state information which is inputted by a user and is related to an endometrial cancer sample, and the information contains genomics, apparent and expressive data and clinical pathology data; the data processing module is configured to sequentially execute multi-level typing logic based on the state information, and the logic comprises the following steps: typing based on POLE gene mutation state preferentially, then typing based on mismatch repair function and p53 function state in sequence aiming at an unshaped sample, and finally carrying out joint layering based on prognosis association indexes; and the typing result output module is used for outputting the final molecular subtype. Through multi-dimensional data cross validation and dynamic layering, the problems that an existing typing technology is single in dimension and poor in clinical applicability are solved, accurate and efficient typing of endometrial cancer is achieved, and reliable technical support is provided for individualized diagnosis and treatment.

The application provides a method for constructing an endometrial carcinoma CT image segmentation model and application thereof, including the following steps: acquiring multiple endometrial CT images labeled with cancerous regions as a training data set; constructing an endometrial carcinoma CT image segmentation architecture, wherein the endometrial carcinoma CT image segmentation architecture is a U-Net structure including an encoding unit, a bottleneck layer and a decoding unit; and training the endometrial carcinoma CT image segmentation architecture with the training data set to obtain an endometrial carcinoma CT image segmentation model. The scheme explicitly captures multi-scale structural change information by constructing a multi-directional coding structure response operator and generating a coding structure gradient field, thereby strengthening the representation of thin and weak boundaries and small lesions to improve the segmentation accuracy of the model.

This disclosure relates to methods, compositions, and combinations for treating endometrial cancer. Specifically, this disclosure relates to methods for treating endometrial cancer in a subject of need, including administering to the subject one or more chemotherapeutic agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor. This disclosure also relates to combinations for use in treating endometrial cancer, comprising one or more chemotherapeutic agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor.

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to restore activity of von Hippel Lindau tumor suppressor protein (pVHL). Such compounds and compositions can be useful in, for example, the treatment of cancer (e.g.. a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)) and von Hippel-Lindau disease (VHLD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Disclosed herein are crystalline polymorphs of indotecan (LMP400) that can be used in the treatment of cancers associated with dysregulation of Topl and / or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a. glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The application provides a kind of detection method and system of endometrial carcinoma based on deep learning, it is related to cancer detection technical field, the method comprises: obtaining preliminary survey data;Determine the preliminary survey result;Determine whether to need to carry out histopathological examination;If it needs to carry out histopathological examination, obtain the hysteroscopy guided biopsy data of patient to be measured, determine the histopathological diagnosis result;Determine whether to need to carry out further detection;If it needs to carry out further detection, obtain the patient physiological state data, medical image data and laboratory test data of patient to be measured;Determine patient physiological state influence coefficient;The medical image data, laboratory test data and patient physiological state influence coefficient are handled by the trained tumor deterioration time prediction model, determine the predicted tumor deterioration time;Determine endometrial carcinoma risk coefficient;Generation detection report.According to the application, the accuracy of the detection result of endometrial carcinoma can be improved.

Disclosed herein are crystalline polymorphs of LMP744 that can be used in the treatment of cancers associated with dysregulation of Top1 and / or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching m the particular art and is not intended to be limiting of the present invention.

The utility model discloses a kind of culture devices for endometrial carcinoma organoids, including culture mechanism and speed control mechanism, the culture mechanism includes culture base, the infusion tube of top portion of culture base is arranged in the inclination, the pipe head being connected with the bottom end of the infusion tube, the graduated cylinder being sleeved in the top end of the infusion tube, speed control mechanism, the speed control mechanism includes two stop blocks one and multiple stop blocks two being connected with the bottom of the infusion tube inner cavity.The utility model in, liquid in graduated cylinder flows through infusion tube, then from pipe head place enters into culture base, in this process, culture solution passes through stop block one and multiple stop blocks two, when passing through stop block one, culture solution is shunted into two, two culture solution respectively collides two stop blocks two, stop block two buffer culture solution flow rate, and make it again branch, effectively avoid culture solution splash phenomenon.

The invention discloses application of a substance for inhibiting polyamine synthesis in preparation of a medicine for treating or relieving endometrial cancer. According to experimental verification of an endometrial cancer cell model and an animal model, it is found that high-fat culture promotes rise of endometrial cancer cell ODC1 and accumulation of polyamine metabolites; mouse serum polyamine metabolites can be up-regulated by feeding the bilateral ovariectomy mouse with high fat; oA-induced polyamine metabolite accumulation and invasion and migration of endometrial cancer cells can be inhibited by knocking down the ODC1; in an animal model, ODC1 is knocked out, and transplantation tumor growth and lymph node metastasis promoted by high fat can also be inhibited by applying an ODC1 inhibitor DFMO. The DFMO can improve the sensitivity of endometrial cancer patients which are resistant to chemotherapeutic drugs. The invention finds that the serum polyamine can be used as a target for developing a medicine for treating or relieving endometrial cancer, and can also be used as a marker for grouping endometrial cancer patients of mammals.

The invention provides a method and system for detecting the malignant degree of endometrial cancer cells, and the method comprises the following steps: judging the influence mechanism of leptin on the malignant degree of cancer cells by detecting parameters such as leptin concentration, JAK2 / STAT3 pathway activation degree, cell proliferation activity, migration and invasion ability and the like; the dynamic association between the leptin concentration change and the activation state of the JAK2 / STAT3 signal channel can be systematically evaluated, the regulation and control effect of the channel on the proliferation, migration and invasion ability of cancer cells is effectively quantified, and a scientific basis is provided for developing treatment schemes and drugs for endometrial cancer.

The present disclosure discloses a library construction method for detecting endometrial cancer-related gene mutations based on high-throughput sequencing, and belongs to the field of biotechnology. The method can detect the mutation types of endometrial cancer-related genes MSH2, PMS2, MLH1, MSH6 EPCAM, TP53, POLE, and PTEN in surgically removed fresh pathological tissues, formaldehyde-fixed and paraffin-embedded pathological tissues, paraffin sections, and specimens of whole blood, plasma, serum, and pleural effusion, etc. It may be used for multiple target sequences in a single tube to quickly complete the library construction. The entire library construction process only takes 3 hours, and the manual operation only needs 30 minutes. Combined with high-throughput sequencing, the platform may effectively solve the current difficulty in the detection of somatic multi-gene all-exon mutations in clinical endometrial cancer samples based on small numbers of clinical samples, and the cost is low.

Provided herein is technology for endometrial cancer (EC) screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of endometrial cancer and various subtypes of endometrial cancer.

The present disclosure provides methods of treatment comprising anti-EDB antibodies and antibody-drug conjugates. The present disclosure further provides methods of treating EDB+ FN-expressing disorders, such as cancer. In some aspects, the method comprises administration of an anti-EDB+FN ADC to a patient having cancer, such as, for example, non-small cell lung cancer (NSCLC), breast cancer, head and neck cancer, ovarian cancer, thyroid cancer, pancreatic cancer, soft tissue sarcoma, chordoma, hepatocellular carcinoma, kidney cancer, cervical cancer, and endometrial cancer.

The invention relates to an application of a medicine in treating tumor diseases. Specifically, the invention provides the application of the bioactive substance conjugate shown in the formula (I) in the treatment of tumor diseases, and the tumor diseases are particularly preferably used for treating local advanced or metastatic solid tumors which are difficult to treat and cannot be resected by surgery according to the existing standard. Comprise but are not limited to breast cancer, stomach cancer, lung cancer, ovarian cancer, urothelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer and brain tumor.

The present disclosure provides a method for treating, reducing the severity of, or inhibiting the growth of MUC16-expressing cancer (e.g., ovarian cancer or endometrial cancer). In certain embodiments, the method of the present disclosure comprises the step of administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to a programmed cell death 1 (PD-1) receptor, or a bispecific antibody or antigen-binding fragment thereof that specifically binds to mucin 16 (MUC16) and CD28 in combination with a bispecific antibody or antigen-binding fragment thereof that specifically binds to MUC16 and CD3, to a subject in need thereof.

The application relates to the medical technology field, in particular to application of chlorpromazine hydrochloride in treating endometrial carcinoma, wherein the endometrial carcinoma includes type I and type II endometrial carcinoma. It is found through experiments that chlorpromazine hydrochloride has inhibiting effects on the proliferation, clone formation and migration capacity of Ishikawa (ISK cell) and KLE cells of endometrial carcinoma, can induce cell apoptosis, up-regulate the expression of cell PRB, inhibit the phosphorylation of cell AKT, and can inhibit the growth of a subcutaneous transplanted tumor of a mouse, and the effectiveness is proved in a mouse experiment. Therefore, the application provides a new use of an antipsychotic drug chlorpromazine hydrochloride for treating endometrial carcinoma.

The invention discloses application of a platelet activating factor in preparation of a medicine for treating endometrial cancer. Cell experiments and animal in-vivo experiments prove that the platelet activating factor can effectively inhibit proliferation of the endometrial cancer and inhibit in-vivo growth of the endometrial cancer, the targeted binding effect of PAF and ATF3 is clarified, a new method is provided for treatment of the endometrial cancer, and the platelet activating factor is expected to be applied to preparation of drugs for inhibiting proliferation of the endometrial cancer and has a wide application prospect. The invention has important significance for clinical treatment of endometrial cancer.

The application discloses a kind of endometrial carcinoma molecular typing methods based on cascaded multiple instance learning, method is by the binary mask of tumor area generated to endometrial carcinoma whole section image preprocessing, to extract the image block in region of interest and construct instance set by dyeing normalization processing;Using PatchVMamba instance encoder, the feature of each image block in instance set is extracted to obtain the instance feature vector of each image block, and the instance feature bag of each whole section image is formed;Using attention mechanism, the instance feature bag is weighted and aggregated to obtain the slice-level feature representation;The slice-level feature is input into the three binary classifiers arranged in cascade to obtain the probability value corresponding to the three subtypes of endometrial carcinoma respectively, and a unified threshold is used for cascade judgment of the subtype classification of endometrial carcinoma to output the final typing result.The cascaded structure of the application makes the consistency of the typing result and the diagnosis of pathological experts high, and realizes accurate typing.

The invention discloses a microbial marker for predicting the occurrence risk of endometrial cancer and application of the microbial marker, an endometrial microbiome is evaluated to determine that differential microbial genus is lactobacillus, an endometrial cancer microbial strain library is constructed, it can be known from the strain library that a large number of bacteria are inert lactobacillus, and the bacterial strain library can be used for predicting the occurrence risk of the endometrial cancer, so that the occurrence risk of the endometrial cancer can be predicted, and the occurrence risk of the endometrial cancer can be predicted. Therefore, the endometrial cancer differential microbial flora is determined to be lactobacillus inertus, and the lactobacillus inertus is cultured to obtain the microbial marker for detecting the occurrence risk of the endometrial cancer. The microbial marker for predicting the occurrence risk of the endometrial cancer, provided by the invention, is lactobacillus inertus, and can be used for development and application of clinical detection kits for the endometrial cancer in the future by designing specific strain primers; the endometrial cancer microbial strain library provided by the invention can be used for designing potential microbial marker strains of endometrial cancer occurrence risks, and a method for co-culturing the microbial strains and tumor cells can also be used for verifying the influence of the microbial strains on different tumor cells.

The application discloses a use of a HOTAIR-PRC2 blocking agent combined with a progestogen in preparation of a drug for conservation treatment of endometrial cancer. The application provides a use of a HOTAIR-PRC2 specific blocking agent combined with a progestogen, which can synergistically inhibit the progression of endometrial cancer. The HOTAIR-PRC2 specific blocking agent provided by the application can restore the expression of PR, and the combination of the progestogen can synergistically inhibit the proliferation, invasion and migration of tumors, promote cell apoptosis, block the cell cycle, and enhance the treatment effect of the progestogen, thereby providing a new treatment idea for the conservation treatment of endometrial cancer.

The embodiment of the application provides a kind of endometrial carcinoma classification method and system based on adaptive weighted ensemble learning, the method includes obtaining clinical data, and based on clinical data, the weighted training set capable of improving the identification ability of minority class is constructed;Balanced training set is input into initial double-branch characteristic learning model for model training, and target double-branch characteristic learning model is obtained when training ends, based on the encoding feature output by first parallel branch, complex pattern mining model integration framework is constructed, and based on the effective feature output by second parallel branch, supervised machine learning model integration framework is constructed;The verification set constructed in advance is input into complex pattern mining model integration framework and supervised machine learning model integration framework, and the dynamic weight of each integrated model in framework is adjusted based on the performance score output;Based on the prediction rule of the two integrated frameworks integrated after dynamic weight adjustment, data classification operation is carried out, and endometrial carcinoma classification result is obtained.

The invention provides a pharmaceutical composition and application thereof in treatment of endometrial cancer, and relates to the technical field of biological medicine. It is found for the first time that combined use of the KDM1A inhibitor SP-2577 and MPA has a remarkable enhancement effect on inhibition of proliferation and cloning of endometrial cancer cells and promotion of cell apoptosis, and the KDM1A inhibitor SP-2577 and the MPA have a synergistic effect; meanwhile, an in-vivo experiment result further shows that compared with independent medication of MPA or SP-2577, combined use of the KDM1A inhibitor SP-2577 and MPA has more outstanding advantages in the aspect of inhibiting tumor growth. The invention provides the pharmaceutical composition consisting of the KDM1A inhibitor SP-2577 and the MPA, the pharmaceutical composition effectively improves the effect of treating the endometrial cancer by single progestational hormone, and an effective solution is provided for patients with low endometrial cancer progestational hormone sensitivity.